← ANALYST RATINGS · TIPRANKS

Sionna Therapeutics, Inc. (SION): analyst forecast and price target

$3.89 −4.66% close 16.10.26 · market cap $184M · General · Biotechnology IWM 0.01%
Price targets and ratings of

Analyst consensus

Hold

0 Buy10 Hold0 Sell

Ratings of 10 analysts in the last 3 months

12-month forecast

$15.33+294.2% upside

Based on 10 price targets given in the last 3 months, the average target is $15.33, the highest $63.00, the lowest $5.00. The average is +294.2% from the last price of $3.89.

$20.00$40.00$60.00Jan 26AprJulOctJan 27AprJulOctHigh$63.00Average$15.33Low$5.00
Highest target $63.00 Average target $15.33 Lowest target $5.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Gaurav Maini★★★★★★★★★★#2199 · hits 88% · avg +29.5% LifeSci Capital $6.00 Hold +54.2% Reiterated 19.09.26on TipRanks 10:30 −0.9%next day +0.3% · 5 days −13.6%
Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% Guggenheim — Hold — Reiterated 15.09.26on TipRanks Sep 16 07:10 −16.2%next day +2.8% · 5 days −14.9%
Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% Wedbush $5.00 → $6.00+20.0% Hold +54.2% Reiterated 15.09.26on TipRanks 08:08 −16.2%next day +2.8% · 5 days −14.9%
Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% Stifel Nicolaus $7.00 Hold +79.9% Reiterated 15.09.26on TipRanks 06:31 −16.2%next day +2.8% · 5 days −14.9%
Ilya Zubkov★★★★★★★★★★#5009 · hits 59% · avg +9.5% Freedom Capital Markets $38.00 → $5.00−86.8% Hold +28.5% Reiterated 11.08.26on TipRanks 10:21 +13.7%next day +22.3% · 5 days +16.9%
Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% BTIG — Hold — Downgrade 10.08.26on TipRanks 15:25 −91.2%next day +13.7% · 5 days +31.4%
Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% Citizens JMP — Hold — Downgrade 10.08.26on TipRanks 12:00 −91.2%next day +13.7% · 5 days +31.4%
Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% Raymond James — Hold — Downgrade 10.08.26on TipRanks 11:31 −91.2%next day +13.7% · 5 days +31.4%
Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% RBC Capital $23.00 → $5.00−78.3% Hold +28.5% Upgrade 10.08.26on TipRanks 11:13 −91.2%next day +13.7% · 5 days +31.4%
Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% JonesTrading $63.00 Hold +1,519.5% Downgrade 10.08.26on TipRanks 06:50 −91.2%next day +13.7% · 5 days +31.4%
Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% TD Cowen — Buy — Reiterated 17.07.26on TipRanks Jul 24 05:09 +10.1%next day −7.4% · 5 days −6.9%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Sionna Therapeutics, Inc.

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Ritu Baral★★★★★★★★★★TD Cowen · #49
Hits 58%286 of 495 Average return +46.9%
1 year Ritu Baral★★★★★★★★★★TD Cowen · #49
Hits 58%286 of 495 Average return +46.9%
2 years Ritu Baral★★★★★★★★★★TD Cowen · #49
Hits 58%286 of 495 Average return +46.9%

Most profitable

3 months Ritu Baral★★★★★★★★★★TD Cowen · #49
Hits 58%286 of 495 Average return +46.9%
1 year Ritu Baral★★★★★★★★★★TD Cowen · #49
Hits 58%286 of 495 Average return +46.9%
2 years Ritu Baral★★★★★★★★★★TD Cowen · #49
Hits 58%286 of 495 Average return +46.9%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $15.33 at a price of $5.26 (+191.5%); now: $15.33 at $3.89 (+294.2%).

$5.00$10.00$15.00$20.00Sep 15Oct 1Oct 15Top analysts$20.25Average target$15.33Price$3.89

PriceAverage targetTop analysts’ target

Recommendation trend

01020221Oct 25142Nov812Dec1812Jan 26372Feb761Mar751Apr51512May41411Jun31611Jul37101Aug5151Sep3151Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy543300
Buy151416753
Hold111101515
Sell211111

Earnings and sales forecast

Next report: 11.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.64 (from $-0.84 to $-0.36). Last quarter: $-0.66.

Best top-analyst consensus in the sector · General

STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
About Sionna Therapeutics, Inc.
  • CEO: Michael Cloonan
  • Employees: 59
  • 21 Hickory Drive Suite 500, Waltham, MA, 02451, US
  • www.sionnatx.com

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Data from the stock’s TipRanks forecast page, read 60 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗